29.17
+0.18
+(0.62%)
At close: April 11 at 4:00:01 PM EDT
29.75
+0.58
+(1.99%)
After hours: April 11 at 6:01:22 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
714,734
714,734
582,022
437,855
305,440
Cost of Revenue
156,815
156,815
121,236
83,481
55,518
Gross Profit
557,919
557,919
460,786
354,374
249,922
Operating Expense
367,093
367,093
268,756
234,188
162,394
Operating Income
190,826
190,826
192,030
120,186
87,528
Net Non Operating Interest Income Expense
1,046
1,046
-9,027
-15,669
-23,970
Other Income Expense
-68
-68
-9,607
169
-26,130
Pretax Income
191,804
191,804
173,396
104,686
37,428
Tax Provision
46,311
46,311
44,543
-76,782
2,831
Net Income Common Stockholders
145,493
145,493
128,853
181,468
34,597
Diluted NI Available to Com Stockholders
145,493
145,493
128,853
181,468
34,597
Basic EPS
2.15
2.56
2.17
3.07
0.60
Diluted EPS
2.11
2.51
2.13
2.97
0.58
Basic Average Shares
57,188.32
56,885.46
59,469.65
59,173.12
57,531.54
Diluted Average Shares
58,018.17
57,869.92
60,372.40
61,097.05
59,205.21
Total Operating Income as Reported
190,826
190,826
192,030
120,186
87,528
Total Expenses
523,908
523,908
389,992
317,669
217,912
Net Income from Continuing & Discontinued Operation
145,493
145,493
128,853
181,468
34,597
Normalized Income
145,493
145,493
136,109.14
181,468
58,755.90
Interest Income
18,542
18,542
14,730
3,126
224
Interest Expense
17,496
17,496
23,757
18,795
24,194
Net Interest Income
1,046
1,046
-9,027
-15,669
-23,970
EBIT
209,300
209,300
197,153
123,481
61,622
EBITDA
233,412
233,412
221,512
146,866
80,462
Reconciled Cost of Revenue
156,815
156,815
121,236
83,481
55,518
Reconciled Depreciation
24,112
24,112
24,359
23,385
18,840
Net Income from Continuing Operation Net Minority Interest
145,493
145,493
128,853
181,468
34,597
Total Unusual Items Excluding Goodwill
--
--
-9,766
--
-26,146
Total Unusual Items
--
--
-9,766
--
-26,146
Normalized EBITDA
233,412
233,412
231,278
146,866
106,608
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
-2,509.86
--
-1,987.10
12/31/2021 - 8/19/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HALO Halozyme Therapeutics, Inc.
60.22
+4.37%
CPRX Catalyst Pharmaceuticals, Inc.
22.05
+2.80%
TRDA Entrada Therapeutics, Inc.
7.90
+0.64%
KRYS Krystal Biotech, Inc.
165.00
+2.71%
CNTA Centessa Pharmaceuticals plc
11.57
+2.66%
JAZZ Jazz Pharmaceuticals plc
100.50
-1.52%
EWTX Edgewise Therapeutics, Inc.
11.42
-1.30%
MIRM Mirum Pharmaceuticals, Inc.
39.58
+1.18%
BMRN BioMarin Pharmaceutical Inc.
56.82
+0.89%
PVLA Palvella Therapeutics, Inc.
21.76
+9.51%